Hook / Thesis
HealthEquity (HQY) sold off in late August despite beating top- and bottom-line expectations, and the market's narrative quickly pivoted to AI-related 'cash fears' and cautious forward commentary. That reaction created a clean buying window. The company still runs the largest HSA custody business in the U.S., generates meaningful free cash flow, and trades at valuation multiples that imply steady growth rather than disruption.
I think the recent weakness is more sentiment than structural: short interest and elevated short volume show bearish positioning, while the business fundamentals reported earlier this year remain intact. This is a tactical long with a clear entry, stop and target that leans on mean reversion and continued HSA adoption.
What HealthEquity does and why it matters
HealthEquity provides technology-enabled services that help employers and consumers manage health care spending, with a focus on health savings accounts (HSAs). HSAs are sticky, deposit-driven products that accumulate assets over time and produce ongoing custody, investment and servicing revenue.
- Scale: HealthEquity reported 10.6 million HSA accounts and 17.8 million total accounts in fiscal 2026, making it the largest HSA custodian by a wide margin.
- Assets: HSA assets were $36.5 billion, and invested HSA assets were $18.5 billion as of the fiscal 2026 results reported on 02/17/2026.
- Revenue mix: Custody and investment-related revenue tends to grow as assets and account penetration increase, supporting recurring revenue and solid cash flow.
Recent performance and why the market over-reacted
HealthEquity beat Q2 expectations with adjusted EPS of $1.24 and revenue of $350.73 million, both ahead of consensus, but management's incremental change to full-year revenue guidance and unchanged EPS guidance disappointed investors (reported in the note on 08/30/2026). That was the proximate cause of the selloff, but the numbers underneath remain solid:
- Q2 adjusted EPS: $1.24, revenue: $350.73M (beat).
- Fiscal 2026 highlights (reported 02/17/2026): HSAs grew 7% to 10.6M accounts; total accounts were 17.8M; HSA assets rose 14% to $36.5B; investments in HSAs increased 26% to $18.5B.
- Free cash flow is robust at $467.674M and the company has cash of roughly $1.66B on the balance sheet with a modest debt profile (debt-to-equity ~0.47).
Those are not the numbers of a business in secular decline. Instead they show ongoing adoption and asset accumulation that should continue to underpin fees and investment revenue over time.
Valuation framing
HealthEquity's market cap sits around $7.45B while enterprise value is about $8.07B. The stock trades at a trailing P/E in the low 30s (snapshot: ~32.3x) and EV/EBITDA of ~15.7x. Price-to-sales is roughly 5.4x.
Those multiples imply expected steady growth rather than breakout expansion. Given the company's FCF generation (roughly $468M) and large, sticky deposit base, the multiple looks demanding but not out of line for a well-run fintech / custodial franchise. The recent pullback has moved the stock closer to its 10-day and 20-day technicals (10-day SMA ~ $89.71; 20-day SMA ~ $92.41), increasing the probability of a mean-reversion move back toward the 50-day area if sentiment stabilizes.
| Metric | Value |
|---|---|
| Market cap | $7.45B |
| P/E | ~32x |
| EV/EBITDA | ~15.7x |
| Free cash flow | $467.7M |
| Cash | $1.66B |
Why AI fears are overblown
Some investors fear that AI tools - like HealthEquity's HSAnswers - will hollow out account balances or accelerate outflows, reducing fee revenue. That is a plausible long-run risk, but the near-term pictures paints differently:
- AI here is primarily a margin-of-service enhancer - it reduces friction in benefits education and can increase HSA adoption, which should support net new accounts over time (HSAnswers already received awards in 2025).
- Assets in HSAs are driven by payroll contributions and consumer behavior; automated education may actually expand contributions by improving engagement, which would be a revenue tailwind, not a headwind.
- Operationally HealthEquity still posts healthy margins and strong cash flow - the company reported a 67% net income lift in a prior quarter and consistent revenue growth of ~9% in recent periods.
Trade plan (actionable)
My trade is a long with the following parameters: entry at $88.00, stop loss at $79.00, target at $110.00. Risk level: medium. Trade direction: long. Time horizon: long term (180 trading days) - I expect the primary move to unfold over the next several months as sentiment normalizes, seasonal flows into HSAs continue and asset-based revenue reaccelerates.
Rationale for the sizing and horizon:
- Entry at $88 is near short-term support around the 10-day SMA and offers a reasonable buffer to recent intraday lows.
- Stop at $79 protects capital beneath a more structural support area - it preserves position if guidance or fundamentals materially deteriorate.
- Target $110 sits just above the 52-week high of $107.62 and represents a ~25% upside from the $88 entry, consistent with mean-reversion to prior trading bands if sentiment reverses.
Catalysts that could push the trade higher
- Evidence of renewed HSA contribution growth or accelerating HSA assets - asset growth would directly lift custody and investment revenue.
- Positive commentary or proof points on HSAnswers (AI) adoption that show it increases enrollee engagement and contributions.
- Stabilizing guidance or incremental margin improvement in an upcoming quarter that reduces sentiment uncertainty.
- Reduction in short interest or a period of lower short-volume that allows for technical squeeze into the 50-day EMA area.
Risks and counterarguments
- AI leads to lower asset balances: If AI features enable more efficient fund movement into external investments (outside of HealthEquity custody) or if automated advice nudges users to deplete HSA cash, fee pools could shrink. This is the fundamental counterargument and would be meaningful if persistent.
- Guidance disappointment: Management's decision to leave EPS guide unchanged despite a beat created the selloff. If future guidance stays muted, multiples could compress further.
- Regulatory or policy risk: Changes in HSA tax treatment, employer benefits regulation, or plan design could lower new HSA formation or contributions.
- Cybersecurity and fraud: Historically cited as a risk, increased fraud or a significant security incident would damage trust and could accelerate account attrition.
- Valuation sensitivity: Trading at ~32x earnings and ~15.7x EV/EBITDA leaves limited tolerance for disappointment; small misses could drive outsized moves lower.
Counterargument: The smartest short idea here is that AI-driven product improvements accelerate flows out of HealthEquity-controlled investments, structurally reducing a key revenue stream. If we see data showing a sustained decline in average assets per account or unusual outflows that are correlated with AI product launches, that would force a re-evaluation.
What would change my mind
I will reduce conviction or exit the position if HealthEquity reports a sequential decline in HSA assets or invested balances, if guidance is lowered materially, or if we observe a sustained increase in account attrition. Conversely, a clear quarter showing stronger-than-expected asset growth, rising investment penetration, or evidence that AI features are improving contribution behavior would strengthen the thesis and likely accelerate the path to the $110 target.
Conclusion
This is a measured, data-driven long: the business continues to generate free cash flow of roughly $467.7M, holds $1.66B in cash, and manages a large, sticky pool of HSA assets that grew double-digits in several key metrics last fiscal year. The near-term selloff has been driven more by sentiment and guide conservatism than by a sudden structural impairment to the core business. For patient investors willing to accept medium risk, an entry at $88 with a stop at $79 and a 180-day horizon toward $110 offers an asymmetric reward-to-risk profile grounded in fundamentals and technical mean reversion.
Key dates referenced: Q2 earnings coverage 08/27/2026 and commentary on the selloff 08/30/2026. Fiscal 2026 results cited from the company's 02/17/2026 disclosure.